Global Neoantigen Peptides Manufacturing Market, by Scale of operations, 2020-2030 (Value US$ Mn)
Global Neoantigen Peptides Manufacturing Market, by End-Users 2020-2030 (Value US$ Mn)
Global Neoantigen Peptides Manufacturing Market, by Region, 2020-2030 (Value US$ Mn)
North America Neoantigen Peptides Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
Europe Neoantigen Peptides Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
Asia Pacific Neoantigen Peptides Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
Latin America Neoantigen Peptides Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
Middle East & Africa Neoantigen Peptides Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
Rest of Middle East & Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Neoantigen Peptides Manufacturing Market Snapshot
Chapter 4. Global Neoantigen Peptides Manufacturing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Industry Analysis – Porter’s Five Forces Analysis
4.6. Investment and Funding Analysis for Neoantigen Vaccine and Therapeutic Development
4.7. Clinical Trial/Pipeline Analysis for Neoantigen Cancer Vaccine
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Scale of Operations Estimates & Trend Analysis
5.1. By Scale of Operations & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Scale of Operations:
5.2.1. Research / Preclinical
5.2.2. Clinical
5.2.3. Commercial
Chapter 6. Market Segmentation 2: By End-Users Estimates & Trend Analysis
6.1. By End-Users & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By End-Users:
6.2.1. Pharmaceutical/Vaccine Developers Companies
6.2.2. Contract Research Organization (CRO)
6.2.3. Academic and Research Institutes
Chapter 7. Neoantigen Peptides Manufacturing Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts By Scale of Operations, 2021-2034
7.1.2. North America Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts By Therapy, 2021-2034
7.1.3. North America Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts by End-Users, 2021-2034
7.1.4. North America Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
7.2. Europe
7.2.1. Europe Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Scale of Operations, 2021-2034
7.2.2. Europe Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Therapy, 2021-2034
7.2.3. Europe Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts by End-Users, 2021-2034
7.2.4. Europe Neoantigen Peptides Manufacturing Market revenue (US$ Million) by country, 2021-2034
7.3. Asia Pacific
7.3.1. Asia Pacific Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Scale of Operations, 2021-2034
7.3.2. Asia Pacific Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Therapy, 2021-2034
7.3.3. Asia Pacific Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts by End-Users, 2021-2034
7.3.4. Asia Pacific Neoantigen Peptides Manufacturing Market revenue (US$ Million) by country, 2021-2034
7.4. Latin America
7.4.1. Latin America Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Scale of Operations, 2021-2034
7.4.2. Latin America Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Therapy, 2021-2034
7.4.3. Latin America Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts by End-Users, 2021-2034
7.4.4. Latin America Neoantigen Peptides Manufacturing Market revenue (US$ Million) by country, 2021-2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Scale of Operations, 2021-2034
7.5.2. Middle East & Africa Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Therapy, 2021-2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. CPC Scientific Inc
8.2.2. Polypeptide group
8.2.3. Genscript Biotech
8.2.4. Kaneka Eurogentec S.A.
8.2.5. Vivitide
8.2.6. Almac
8.2.7. BCN Peptides
8.2.8. Creative Peptides
8.2.9. Pepscan
8.2.10. Provepharm
8.2.11. Creosalus
8.2.12. Gyros Protein Technologies
8.2.13.AnaSpec
8.2.14. Other Prominent Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.